These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 9241490)

  • 1. Principles of signal detection in pharmacovigilance.
    Meyboom RH; Egberts AC; Edwards IR; Hekster YA; de Koning FH; Gribnau FW
    Drug Saf; 1997 Jun; 16(6):355-65. PubMed ID: 9241490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal selection and follow-up in pharmacovigilance.
    Meyboom RH; Lindquist M; Egberts AC; Edwards IR
    Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thoughts on signal detection in pharmacovigilance.
    Shakir SA
    Drug Saf; 2007; 30(7):603-6. PubMed ID: 17604411
    [No Abstract]   [Full Text] [Related]  

  • 8. Signal detection: historical background.
    Egberts TC
    Drug Saf; 2007; 30(7):607-9. PubMed ID: 17604412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving paradigms in pharmacovigilance.
    Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
    Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief primer on automated signal detection.
    Hauben M
    Ann Pharmacother; 2003; 37(7-8):1117-23. PubMed ID: 12841826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovations for the future of pharmacovigilance.
    Almenoff JS
    Drug Saf; 2007; 30(7):631-3. PubMed ID: 17604419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting.
    Mascolo A; Scavone C; Sessa M; di Mauro G; Cimmaruta D; Orlando V; Rossi F; Sportiello L; Capuano A
    Pharmacol Res; 2017 Sep; 123():122-129. PubMed ID: 28694146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.
    Tomlin A; Reith D; Dovey S; Tilyard M
    Drug Saf; 2012 Sep; 35(9):733-43. PubMed ID: 22861670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The French pharmacovigilance system: structure and missions].
    Welsch M; Alt M; Richard MH; Imbs JL
    Presse Med; 2000 Jan; 29(2):102-6. PubMed ID: 10682040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country.
    Nguyen KD; Nguyen PT; Nguyen HA; Roussin A; Montastruc JL; Bagheri H; Olsson S
    Drug Saf; 2018 Feb; 41(2):151-159. PubMed ID: 28975584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.